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Background: Interleukin 17F (IL-17F) is a pro-inflammatory cytokine that is recently proved to have a
crucial role in the emergence of autoimmune diseases; it induces the expression of various cytokines,
chemokines, and adhesion molecules. IL-17F polymorphism is subsequently related to enhanced IL-17F
expression and activity; which may result in susceptibility to many autoimmune diseases including pri-
mary immune thrombocytopenia (PIT).
Aim of the study: This case-control study aimed to investigate the possible association between IL and 17F
gene single nucleotide polymorphism (SNP) at rs 7488A/G and PIT susceptibility in Egyptian pediatric
patients.
Subjects and methods: A total of 50 children with PIT with a mean age of 7 years, together with 50 age and
sexmatched healthy controls were enrolled in the study for evaluation. Polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) was used for detection of IL-17F polymorphism
at rs7488A/G.
Results: Regarding the genotypes distribution, the frequencies of the AA, AG and GG genotypes were 96,
2, and 2% in PIT patients and 90, 10 and 0% in the control group respectively. The A and G allele frequen-
cies were 97 and 3% in the patients’ group versus 95 and 5% in the control group. There was no significant
difference in either genotypes or allelic distribution between PIT patients and the controls.
Conclusion: Our study suggests that IL17F gene polymorphism at rs7488A/G may not contribute to the
susceptibility in development of primary immune thrombocytopenia in the Egyptian children.
 2018 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Primary immune thrombocytopenia (PIT) is an acquired
autoimmune disorder characterized by a low platelet count that
occurs in the absence of underlying disease; which is attributed
to the vagueness of the disease’s pathogenesis. Decreased platelet
count usually results from increased platelet destruction together
with inadequate platelet production [1].
PIT is considered the most common autoimmune cytopenia in
the childhood; 2.2–5.3 per 100,000 children aged 18 years or less
are diagnosed with PIT every year [2]. Fortunately, childhood PIT
is known to have a favorable prognosis [3].
Though the pathogenesis of PIT is still rendered unclear, yet
there are many theories that emphasize the involvement of multi-
ple mechanisms comprising antiplatelet antibodies secreted byauto-reactive B lymphocytes, platelet destruction mediated by T
cells, poor functionality of regulatory T cells accompanied with
their reduced number [4].
Innovative data had supported the hypothesis of CD4 T cell
plasticity which in turn leads to diverse immune responses, based
on the type of impact made by the inflammatory environment; this
could be exemplified in T helper 17 (Th17) cell that can easily
become an Interferon c (IFN-c) producer [5].
CD4 T cells are capable to modify their profile for which inter-
leukin they are going to produce; in addition they can attain
‘‘mixed” phenotype features in a classically defined lineage [6].
Thus, nowadays their role is now interpreted as network of
responses rather than distinctive elements [7], since the balance
between these subsets has been involved in the regulation of sev-
eral immune responses [1]. Ogawara et al. [8] had shown that
increased T helper 1/T helper 2 (Th1/Th2) ratio was correlated with
PIT development. Moreover, another study made by Ji et al. [9] had
shown the role of up-regulated Th 17 cells in the pathogenesis of
PIT.
386 S.K.A. Botros et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 385–389IL-17F is a signature cytokine secreted from Th17 cells, apart
from playing a crucial role in the defensive mechanism against
pathogens and autoimmunity; it has shown to function differently
from other members of the IL-17 cytokine family, especially IL-
17A. Hence IL-17F is considered a principal mediator of cellular
immunity by preserving the expression of essential cytokines that
induce pro-inflammatory responses [10].
IL-17F gene is located on chromosome No. 6p 12.3, it has 3
exons interposed with 2 introns [11]. IL-17F rs763780 polymor-
phism affects the coding region of the gene by causing Histidine
to Arginine (His-to-Arg) substitution at amino acid 161, this SNP
leads to up-regulation of IL-17F and consequently the development
of autoimmune diseases comprising PIT [12].2. Aim of the study
This is a case-control study aiming to analyze IL-17F polymor-
phism at rs7488A/G among Egyptian children diagnosed with PIT
and healthy children to evaluate its contribution to PIT
susceptibility.3. Subjects and methods
3.1. Subjects
This case-control study involved a total of 50 Egyptian pediatric
patients diagnosed with ITP (28 acute and 22 chronic) who
attended the Pediatric Hematology outpatient clinic – Abu El Rish
– Cairo University Hospital, as well as 50 age and sex matched
healthy children as controls. Thereafter an informed consent was
attained from each participant or from his/her guardians. The
study was approved by Ethical Committee of Clinical Pathology,
Cairo University. An informed written consent was obtained from
all the patients participating in the study. The work has been car-
ried out in accordance with the code of ethics of the World Medical
Association (Declaration of Helsinki) for experiments in humans.
PIT diagnosis was established via history taking together with
physical examination and laboratory investigations. Inclusion cri-
teria were obtained for these patients and incorporated a Complete
Blood Count (CBC) results that revealed an isolated thrombocy-
topenia (<100  109/l), without anemia or leucopenia and Bone
Marrow Aspirate (BMA) that showed a megakaryocytic morphol-
ogy compatible with the diagnosis of PIT. Furthermore; patient’s
history showed no concomitant autoimmune disorders, no medi-
cations known to cause thrombocytopenia, no associated viral dis-
orders or suspicion of malignancy. Exclusion criteria comprised
infants with age <6 months, manifestations of active infection,
splenomegaly and secondary causes of PIT, such as systemic lupus
erythematosis (SLE). Nonetheless, a further classification was done
on our PIT patients based on the duration of the disease. They were
divided into acute ‘‘newly diagnosed” cases as well as chronic cases
of more than 12 months duration. The disease duration in our PIT
chronic patients ranged from 13 to 48 months with a median of 30
months. Peripheral blood samples were withdrawn from all the
acute cases before starting any medications. On the other hand,
PIT chronic cases were receiving Glucocorticoids as the main line
of treatment in such cases, but none of them had been treated with
it at least 4 months prior to sampling.
3.2. Methods
3.2.1. Genomic DNA extraction
Two ml of anti-coagulated peripheral venous blood were with-
drawn from all ITP cases as well as controls for Genomic DNA
extraction using Prime-Prep Genomic DNA Isolation Kit (GENETBIO, Korea), manufacturers’ instructions were followed and
extracted DNA samples were stored at 20.
3.2.2. Genotyping
IL-17F + A/G genotyping was carried out by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP)
technique using TECHNE, Thermal Cycler instruments (TECHNE,
Version 3.1) and the following pairs of primers were used: forward
primer: 50 GTTCCCATCCAGCAAGAGAC-30, reverse primer: 5-
AGCTGGGAATGCAAACAAAC-30[13,14].
The PCR cycles conditions were as follows: 94 C for 3 min; 35
cycles at 94 C for 30 s, 60 C for 30 s and 72 C for 30 s; and a final
elongation step at 72 C for 7 min. The PCR products were visual-
ized after electrophoresis in 2% agarose gel and ethidium bromide
staining under UV light (Uvitec). The amplified PCR products were
digested with the NlaIII restriction endonuclease (New England
BioLabs Inc.) and analyzed in 2% agarose gel. Three patterns were
observed following digestion and electrophoresis: a single 412 bp
fragment (individuals homozygous for the IL-17F G allele, lacking
the NlaIII site), three fragments of 412, 288 and 124 bp in length
(heterozygous individuals) or two fragments of 288 and 124 bp
(individuals homozygous for the IL-17F A allele).
3.2.3. Statistical methods
Data management and analysis were performed using Statisti-
cal Package for Social Sciences (SPSS-17). Numerical data were
summarized using means and standard deviations or medians
and ranges. Categorical data were summarized as percentages.
Comparisons between the two groups with respect to numeric
variables were done by the Mann-Whitney test. To compare more
than two groups with respect to numeric variables, Kruskal-Wallis
test followed by the post hoc Dunn test for non-parametric data
was performed. The chi-square test was used to compare the
groups with respect to categorical data. To assess the degree of
association between the numeric variables, the Spearman correla-
tion for nonparametric data was used. P values 0.05 were consid-
ered significant.4. Results
The study involved 50 patients suffering from ITP; 22 (44%) of
them fulfilled the criteria of chronic PIT [11 (50%) boys and 11
(50%) girls]; their mean age was 7.91 ± 3.37. 28 (56%) children
had acute ITP [16 (57.1%) boys and 12 (57.1%) girls]; their mean
age was 6.29 ± 3.49 years. In addition, 50 age and Sex-matched
healthy children [28 (57.0%) boys and 22 (43.0%) girls] were
included as a control group. Their mean age was 7.42 ± 3.21 years.
The descriptive data of the studied subjects are illustrated in
Table 1 and 2.
Regarding genotypes distribution, the wild genotype (AA) fre-
quency was 96% in the PIT patients compared to 90% in the control
group. The heterozygous mutant (AG) genotype frequency was 2%
in PIT group compared to 10% in the control group while the
homozygous mutant (GG) genotype frequency was 2% and 0%
respectively in patients and control groups, The difference in geno-
types distribution (AG, AA, GG) was not statistically significant (p
= 0.1, 0.3, 0.5 respectively).
Similarly, the frequency of both homozygous GG and heterozy-
gous AG mutant genotypes was comparable between both groups
(4% vs 10% in cases and control groups respectively, p = 0.24).
On the other hand, our study showed no statistically significant
difference between the allelic distribution of the IL17F (A7488G)
SNP in the studied groups; where the mutant allele G frequency
was 3% and 5% in patients and control groups respectively, (p =
0.47). Data are presented in Table 3 and 4 and Fig. 1.
Table 1
Clinical and laboratory characteristics of ITP patients.
ITP (n = 50) Acute ITP
(n = 28) (56%)
Chronic ITP
(n = 22) (44%)
Age (years)
Range 2–14 2–13 2–14
Mean ± SD 7 ± 3.50 6.29 ± 3.49 7.91 ± 3.37
Sex (no, %)
Male 27 (54%) 16 (57.1%) 11 (50%)
Female 23 (46%) 12 (42.9%) 11 (50%)
Management
Corticosteroids 50 (100%) 28 (100%) 22 (100%)
IV Ig 7 (14%) 3 (10.7%) 4 (18.2%)
Immunosuppressive 10 (20.0%) 1 (3.6%) 9 (40.9%)
PLT transfusion 4 (8%) 3 (10.7%) 1 (4.5%)
Laboratory data
Hemoglobin (g/dl)
Range 7–13 7–13 8–13
Mean ± SD 10.23 ± 1.60 9.95 ± 1.62 10.60 ± 1.53
TLC (109/l)
Range 4.1–15.4 5.8–15.4 4.1–15
Mean ± SD 9.19 ± 2.47 9.41 ± 2.49 8.92 ± 3.07
Platelets (109/l)
Range 5–216 5–87 55–216
Mean ± SD 72.42 ± 56.15 31.79 ± 22.47 124.14 ± 41.29
Table 2
clinical and laboratory characteristics of the control
group.
Item Control group (n = 50)
Age (years)
Range 1–13







Mean ± SD 13.15 ± 1.026
TLC (109/l)
Range 4.3–11
Mean ± SD 7.595 ± 1.7837
Platelets (109/l)
Range 155–432
Mean ± SD 291.48 ± 69.96
Table 3
IL17F genotype allelic Frequencies between PIT patients and the Control group.
IL17F Genotypes Group
Control N = 50
Hetero AG 5 (10.0%)
Homo AA 45 (90.0%)
Homo GG 0 (0.0%)
Total A allele 95 (95.0%)
G allele 5 (5.0%)
Table 4
IL17F genotype allelic distribution of the total of homozygous and heterozygous frequenc





















Fig. 1. Distribution of IL17F genotype allelic frequencies between the studied
groups: (Hetero AG, Homo. AA and Homo GG).
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ease severity in terms of onset, the degree of thrombocytopenia,
response to glucocorticoid therapy could not be assessed owing
to the small number of patients [2 (4%)] having the mutation.
5. Discussion
IL-17 is a potent pro-inflammatory cytokine that is able to
recruit neutrophils and monocytes and induce the activation of
various cytokines, including IL-1, IL-6, IL-8, and interferon-ɤ (IFN-
ɤ) and thus ending up in an immune-mediated inflammatory reac-
tion via the expression of IL-17 receptors [15]. Several studies
demonstrated that genetic polymorphisms of IL-17 were shown
to be linked to various autoimmune diseases such as inflammatory
bowel disease, asthma, and PIT [16].
In the present study, no association was found between the
IL17F (rs7488A/G) SNP and PIT susceptibility in the studied popu-
lation, both genotypes and allelic distribution were comparable
among patients and control groups.
Lately, IL-17F genetic polymorphism has been the centre of
attraction since various studies have been executed to validate
the potential role of this genetic polymorphism in development
of different autoimmune diseases such as rheumatoid arthritis
[17,18], psoriasis [19], multiple sclerosis [20], together with hema-
tological diseases such as acute myeloid leukemia [21], and non-
hematological malignancies including gastric cancer [22], lung
cancer [23] and colo-rectal cancer [24,25].
The results obtained in this study showed that the Wild geno-
type AA frequency was 96% in the PIT patients compared to 90%Total P. value
ITP N = 50
1 (2.0%) 6 0.3
48 (96.0%) 93 0.1
1 (2.0%) 1 0.5
97 (97.0%) 192 (96.0%) 0.47
3 (3.0%) 8 (4.0%)
ies in the studied groups.
ITP N = 50 Total P. Value
2 (4.0%) 7 0.24
48 (96.0%) 93
388 S.K.A. Botros et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 385–389in the control group. The Heterozygous mutant genotype fre-
quency (AG) was 2% in PIT group compared to 10% in the control
group while the homozygous mutant genotype (GG) frequency
was 2% and 0% respectively in patients and control groups, with
no statistical difference in the genotypes distribution (AG, AA,
GG) (p = 0.1, 0.3, 0.5 respectively). Furthermore, there was no sta-
tistical difference between the allelic distribution (A allele, G allele)
in the studied groups; where the mutant allele frequency (G) was
3% and 5% in patients and control groups respectively, (p = 0.47).
Regarding genotype distribution, our results were consistent
with Li et al., 2015. However, this study showed that G (mutant)
allele in PIT patients was significantly lower than in normal con-
trols (total PIT 3.6% vs controls 7.7%, P = .026; chronic PIT 3.5% vs
controls 7.7%, P = .031). Moreover, in their study, there was no
association between IL and 17F polymorphisms and any of the clin-
ical parameters in PIT patients, also the study revealed no associa-
tion between gene distribution and acute onset of the disease, age,
glucocorticoids therapy or disease course.
IL17F 7488A/G SNP association with various autoimmune dis-
eases was a focus for research, Erkol et al. [26] demonstrated in
their study the influence of polymorphisms of interleukin-17A
and -17F genes on susceptibility and activity of rheumatoid arthri-
tis. They found no significant difference regarding genotypes or
allelic frequency distributions of the IL-17A G197A, the IL-17F
7383A/G, and 7488A/G polymorphisms between patients and
healthy controls.
Previous studies of the association of IL17F SNP and PIT yielded
variable results, for instance, a study by Saitoh et al., [12] showed
that the frequency of the IL-17F 7488 mutant Arg161 genotype is
significantly lower among the chronic PIT patient group in compar-
ison to the control group (0% vs. 4.8%, P < 0.05). This inferred that
IL-17F 7488 mutant (GG) genotype has less ability to potentiate
an immunologic reaction in the development of chronic PIT.
Moreover, another recent study executed by Liu et al. [27] on
Chinese patients revealed that the frequencies of IL-17F
‘‘A7488G” wild allele A were significantly higher in PIT patients
in comparison to the healthy controls with a result of 31.85% vs.
18.98% and a P value of <0.01. Furthermore, PIT patients had signif-
icantly higher frequencies of AA and AG genotypes than the
healthy controls, these findings could validate the incrimination
of IL17 F polymorphism in PIT development in such patients.
On the other hand, an Egyptian study was done by Mokhtar
et al., [4] aimed to investigate the possible association between
PIT development in the childhood and the several genetic polymor-
phisms in tumor necrosis factor (TNF)-alpha, interleukin (IL)-10,
IL-6, IL-17 and IL-1Ra, the results obtained revealed a significant
higher mutant genotype of IL-17F (P = 0.0001) among the patient’s
group compared to the control group yet the discrepancies
between our results and these results could be attributed to the
ethnic difference between the studied populations, the frequency
of the variant allele being low in both the patient and control
groups in the present work.
The study limitations here could be attributed to the relatively
small sample size enrolled in the study, thus further studies with
larger cohorts are recommended to validate the role of these SNPs
as molecular contributors to the addressed pathology. Likewise, IL-
17F serum levels should have been examined in order to study the
link between the studied genetic polymorphism and its serum
levels.6. Conclusion
IL17F gene polymorphism might not contribute to the suscepti-
bility of primary immune thrombocytopenia development in the
Egyptian children, yet it has to be stated that further investigationswith larger cohorts are recommended for better characterization of
patients prone for disease as well as for identification of other
novel molecular markers that could impact the disease course
and consequently disease morbidity and mortality.
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The influence of polymorphisms of interleukin-17A and-17F genes on
susceptibility and activity of rheumatoid arthritis. Genet Test Mol
Biomarkers 2015;19(8):461–4.
[27] Liu S, Xiong YZ, Li T, Li Y, Gu SQ, Wang YM, et al. Interleukin-17A and-17F Gene
polymorphisms in Chinese population with chronic immune
thrombocytopenia. Ann Clin Lab Sci 2016;46(3):291–7.
